Clinical Overview
Eszopiclone is a nonbenzodiazepine hypnotic indicated for the treatment of insomnia. As a cyclopyrrolone derivative, it selectively binds to GABA-A receptors to promote sleep initiation and maintenance while having less impact on sleep architecture compared to traditional benzodiazepines.
Primary Clinical Applications
Eszopiclone is effective for both sleep onset and sleep maintenance insomnia. It has been studied for long-term use (up to 6 months) and may be appropriate for chronic insomnia when non-pharmacological interventions are insufficient. It provides 7-8 hours of sleep without significant next-day impairment.
Mechanism and Sleep Benefits
Eszopiclone acts as a positive allosteric modulator of GABA-A receptors, particularly those containing alpha-1 subunits. This selective binding promotes sleep while preserving normal sleep stages and reducing rebound insomnia compared to traditional sedative-hypnotics.
Clinical Considerations
The medication should be taken immediately before bedtime with at least 7-8 hours available for sleep. It has a relatively short half-life (6 hours) which minimizes next-day sedation. Tolerance and dependence potential exists but may be lower than traditional benzodiazepines.
Prescribing Information
Dosing & Administration
Insomnia – Adults:
- Initial: 1 mg immediately before bedtime
- Range: 1-3 mg once daily
- Maximum: 3 mg once daily
- Sleep duration required: 7-8 hours
Elderly (≥65 years):
- Initial and maximum: 1 mg immediately before bedtime
- Sleep maintenance difficulty: May increase to 2 mg if needed
Hepatic Impairment:
- Severe impairment: 1 mg immediately before bedtime
Administration:
- Take immediately before bedtime
- Ensure 7-8 hours available for sleep
- Do not take with or after a high-fat meal
Indications
- Treatment of insomnia
- Difficulty with sleep onset and/or sleep maintenance
Contraindications
- Hypersensitivity to eszopiclone or any component
- No absolute contraindications
Warnings & Precautions
- Complex sleep behaviors: Sleep-driving, sleep-eating, and other activities while not fully awake may occur without alcohol or other CNS depressants; discontinue immediately if these occur
- CNS depression: Risk increased with alcohol and other CNS depressants
- Next-day impairment: Dose-dependent risk, especially at ≥2–3 mg; use caution with activities requiring alertness the next day
- Dependence and withdrawal: Risk with prolonged use
- Suicidal ideation: Monitor for mood changes
- Respiratory depression: Risk in patients with compromised respiratory function
Drug Interactions
- CNS depressants: Enhanced sedation and respiratory depression
- Alcohol: Contraindicated – dangerous potentiation
- Strong CYP3A4 inhibitors: Reduce eszopiclone dose to 1 mg
- CYP3A4 inducers: May reduce eszopiclone effectiveness
Adverse Reactions
Common (≥2%):
- Unpleasant taste (metallic), headache, somnolence
- Dizziness, dry mouth, dyspepsia
Serious:
- Complex sleep behaviors, severe allergic reactions
- Depression, suicidal ideation
Special Populations
- Elderly: Increased sensitivity, maximum 2 mg daily
- Hepatic Impairment: Severe impairment maximum 1 mg daily
- Pregnancy: Category C – use only if benefits outweigh risks
- Dependence Risk: Limit duration when possible, taper gradually
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
